Adaptimmune Therapeutics (ADAP) Short Interest Ratio & Short Volume $0.29 +0.01 (+3.72%) As of 12:34 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Adaptimmune Therapeutics Short Interest DataAdaptimmune Therapeutics (ADAP) has a short interest of 4.59 million shares, representing 2.05% of the float (the number of shares available for trading by the public). This marks a -15.78% decrease in short interest from the previous month. The short interest ratio (days to cover) is 2.8, indicating that it would take 2.8 days of the average trading volume of 1.75 million shares to cover all short positions.Current Short Interest4,590,000 sharesPrevious Short Interest5,450,000 sharesChange Vs. Previous Month-15.78%Dollar Volume Sold Short$1.15 millionShort Interest Ratio2.8 Days to CoverLast Record DateApril 15, 2025Outstanding Shares257,232,000 sharesShort Percent of Float2.05%Today's Trading Volume255,085 sharesAverage Trading Volume1,752,754 sharesToday's Volume Vs. Average15% Short Selling Adaptimmune Therapeutics? Sign up to receive the latest short interest report for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartADAP Short Interest Over TimeADAP Days to Cover Over TimeADAP Percentage of Float Shorted Over Time Adaptimmune Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20254,590,000 shares $1.15 million -15.8%2.0%2.8 $0.25 3/31/20255,450,000 shares $1.07 million -3.4%2.4%3.2 $0.20 3/15/20255,640,000 shares $2.54 million -11.3%2.5%3.3 $0.45 2/28/20256,360,000 shares $3.43 million -11.5%2.8%4 $0.54 2/15/20257,190,000 shares $4.16 million +4.5%3.2%4.3 $0.58 1/31/20256,880,000 shares $4.06 million +19.4%N/A3.4 $0.59 1/15/20255,760,000 shares $3.50 million +4.7%N/A2.7 $0.61 12/31/20245,500,000 shares $2.96 million +8.7%N/A2.6 $0.54 12/15/20245,060,000 shares $2.94 million -24.7%N/A2.8 $0.58 11/30/20246,720,000 shares $4.84 million -2.8%N/A4.1 $0.72 Get the Latest News and Ratings for ADAP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/15/20246,910,000 shares $4.05 million +29.2%N/A4.7 $0.59 10/31/20245,350,000 shares $3.88 million -3.8%N/A4.5 $0.73 10/15/20245,560,000 shares $4.89 million -8.7%N/A3.5 $0.88 9/30/20246,090,000 shares $5.79 million -13.0%N/A3.6 $0.95 9/15/20247,000,000 shares $7.77 million +2.5%N/A3.9 $1.11 8/31/20246,830,000 shares $8.67 million -4.2%N/A3.7 $1.27 8/15/20247,130,000 shares $7.77 million No ChangeN/A3.3 $1.09 7/31/20247,130,000 shares $9.48 million +13.2%N/A3.5 $1.33 7/15/20246,300,000 shares $7.84 million +11.7%N/A4 $1.25 6/30/20245,640,000 shares $5.50 million +15.1%N/A3.6 $0.97 6/15/20244,900,000 shares $4.95 million +6.1%N/A3.3 $1.01 5/31/20244,620,000 shares $5.22 million +34.3%N/A2.8 $1.13 5/15/20243,440,000 shares $4.27 million -2.3%N/A2.5 $1.24 4/30/20243,520,000 shares $4.19 million +3.2%N/A2.3 $1.19 4/15/20243,410,000 shares $3.58 million +6.6%N/A1.7 $1.05 3/31/20243,200,000 shares $5.06 million +2.9%N/A1.7 $1.58 3/15/20243,110,000 shares $4.60 million +11.1%N/A1.7 $1.48 2/29/20242,800,000 shares $4.40 million -4.4%N/A1.6 $1.57 2/15/20242,930,000 shares $3.66 million -37.8%N/A2.1 $1.25 1/31/20244,710,000 shares $4.52 million -18.4%N/A3.8 $0.96 1/15/20245,770,000 shares $4.75 million +1.2%N/A9.3 $0.82 12/31/20235,700,000 shares $4.52 million -6.9%N/A9.6 $0.79 12/15/20236,120,000 shares $2.75 million -0.8%N/A12 $0.45 11/30/20236,170,000 shares $3.09 million +3.0%N/A14.4 $0.50 11/15/20235,990,000 shares $3.00 million +2.4%N/A14.3 $0.50 10/31/20235,850,000 shares $3.16 million -12.6%N/A14.2 $0.54 10/15/20236,690,000 shares $4.39 million +12.1%N/A14.7 $0.66 9/30/20235,970,000 shares $4.66 million -1.3%N/A12.2 $0.78 9/15/20236,050,000 shares $4.91 million +3.1%N/A10.3 $0.81 8/31/20235,870,000 shares $4.58 million +1.9%N/A8.3 $0.78Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 8/15/20235,760,000 shares $4.49 million +0.4%N/A6.5 $0.78 7/31/20235,740,000 shares $5.41 million +1.4%3.9%6.5 $0.94 7/15/20235,660,000 shares $5.10 million -5.5%3.8%6.2 $0.90 6/30/20235,990,000 shares $5.54 million -19.6%4.1%6.3 $0.93 6/15/20237,450,000 shares $7.52 million -25.2%5.1%8.4 $1.01 5/31/20239,960,000 shares $10.16 million +8.7%6.8%11.6 $1.02 5/15/20239,160,000 shares $12.73 million +2.0%6.2%12.1 $1.39 4/30/20238,980,000 shares $12.75 million +19.9%6.2%12.5 $1.42 4/15/20237,490,000 shares $10.19 million +11.3%5.1%11.6 $1.36 3/31/20236,730,000 shares $7.34 million +28.7%4.6%11.9 $1.09 3/15/20235,230,000 shares $5.91 million +81.0%3.6%9.6 $1.13 2/28/20232,890,000 shares $5.12 million +1.8%2.0%6.5 $1.77 2/15/20232,840,000 shares $4.69 million +1.4%2.0%8.4 $1.65 1/31/20232,800,000 shares $5.24 million +3.3%1.9%6.4 $1.87 1/15/20232,710,000 shares $5.07 million -8.1%1.9%5.1 $1.87 12/30/20222,950,000 shares $4.31 million +7.7%2.0%5.6 $1.46 12/15/20222,740,000 shares $3.73 million -1.4%1.9%5.3 $1.36 11/30/20222,780,000 shares $6.03 million -26.1%1.9%5.3 $2.17 11/15/20223,760,000 shares $8.95 million +12.6%2.6%7.6 $2.38 10/31/20223,340,000 shares $4.74 million -10.0%2.3%7.9 $1.42 10/15/20223,710,000 shares $4.19 million -6.6%2.6%9.3 $1.13 9/30/20223,970,000 shares $4.27 million +7.0%2.8%13.5 $1.08 9/15/20223,710,000 shares $6.01 million +0.3%2.6%12.3 $1.62 8/31/20223,700,000 shares $7.33 million +1.7%2.6%11.6 $1.98 8/15/20223,640,000 shares $8.77 million -2.2%2.5%10.6 $2.41 7/31/20223,720,000 shares $6.88 million -7.9%2.6%9.7 $1.85 7/15/20224,040,000 shares $6.91 million +3.3%2.8%8.4 $1.71 6/30/20223,910,000 shares $6.65 million -4.6%2.7%6.9 $1.70 6/15/20224,100,000 shares $6.60 million -4.7%2.9%7.2 $1.61 5/31/20224,300,000 shares $6.19 million +0.5%3.1%6 $1.44 5/15/20224,280,000 shares $6.03 million -5.5%3.1%4.4 $1.41 4/30/20224,530,000 shares $7.79 million -2.2%3.3%4.5 $1.72 4/15/20224,630,000 shares $8.84 million -0.4%3.4%4.9 $1.91 3/31/20224,650,000 shares $9.58 million -10.2%3.4%4.8 $2.06 3/15/20225,180,000 shares $8.96 million -3.2%3.8%5.1 $1.73 2/28/20225,350,000 shares $13.91 million -2.4%3.9%5.4 $2.60 2/15/20225,480,000 shares $17.37 million +3.0%4.0%7.1 $3.17 1/31/20225,320,000 shares $15.53 million +4.1%3.9%6 $2.92 1/15/20225,110,000 shares $16.86 million +5.6%3.7%5.9 $3.30 12/31/20214,840,000 shares $18.15 million +29.4%3.5%5.8 $3.75 12/15/20213,740,000 shares $13.76 million +10.7%2.7%4.4 $3.68 11/30/20213,380,000 shares $14.03 million +8.3%2.5%3 $4.15 11/15/20213,120,000 shares $13.57 million +5.8%2.3%1.6 $4.35 10/29/20212,950,000 shares $14.96 million -3.9%2.2%1.5 $5.07 10/15/20213,070,000 shares $16.36 million -8.4%2.2%1.6 $5.33 9/30/20213,350,000 shares $17.32 million -44.9%2.4%1.8 $5.17 9/15/20216,080,000 shares $32.83 million +47.9%4.4%3.3 $5.40 8/31/20214,110,000 shares $21.25 million +41.2%3.0%2.5 $5.17 8/13/20212,910,000 shares $11.61 million +8.2%2.1%4 $3.99 7/30/20212,690,000 shares $9.60 million -5.6%2.0%3.3 $3.57Virtually Limitless Energy? (Ad)A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.One company’s discovery could change power forever 7/15/20212,850,000 shares $10.66 million -5.0%2.1%3.3 $3.74 6/30/20213,000,000 shares $12.78 million -21.7%2.2%3.5 $4.26 6/15/20213,830,000 shares $15.86 million -2.5%2.8%4.2 $4.14 5/28/20213,930,000 shares $19.77 million -1.8%2.9%4.7 $5.03 5/14/20214,000,000 shares $18.24 million -0.7%N/A4.8 $4.56 4/30/20214,030,000 shares $23.29 million +5.0%N/A4.6 $5.78 4/15/20213,840,000 shares $19.35 million +27.2%N/A4.4 $5.04 3/31/20213,020,000 shares $15.25 million +64.1%N/A3.1 $5.05 3/15/20211,840,000 shares $10.08 million -0.5%N/A1.5 $5.48 2/26/20211,850,000 shares $10.99 million +22.5%N/A1.3 $5.94 2/12/20211,510,000 shares $10.01 million +4.9%N/A1 $6.63 1/29/20211,440,000 shares $7.89 million +8.3%N/A0.9 $5.48 1/15/20211,330,000 shares $8.11 million -64.1%N/A0.8 $6.10 12/31/20203,700,000 shares $20.02 million +31.2%N/A2 $5.41 12/15/20202,820,000 shares $11.56 million No ChangeN/A1.7 $4.10 11/30/20202,820,000 shares $13.85 million -5.1%N/A2.1 $4.91 11/15/20202,970,000 shares $14.82 million -35.0%N/A2.5 $4.99 10/30/20204,570,000 shares $20.70 million -29.0%N/A4.1 $4.53 10/15/20206,440,000 shares $51.20 million +21.1%N/A7 $7.95 9/30/20205,320,000 shares $42.45 million +8.6%N/A7.5 $7.98 9/15/20204,900,000 shares $49.39 million +50.8%N/A6.3 $10.08 8/31/20203,250,000 shares $28.28 million -18.8%N/A4.1 $8.70 8/14/20204,000,000 shares $32.04 million +2.8%N/A1.3 $8.01 7/31/20203,890,000 shares $36.37 million +3.5%N/A1.2 $9.35 7/15/20203,760,000 shares $31.96 million +1.1%N/A1.2 $8.50 6/30/20203,720,000 shares $34.56 million -5.6%N/A1.2 $9.29 6/15/20203,940,000 shares $41.09 million +605.1%N/A1.3 $10.43 5/29/2020558,800 shares $6.19 million +39.4%N/A0.2 $11.07 5/15/2020401,000 shares $1.74 million -45.2%N/A0.7 $4.35 ADAP Short Interest - Frequently Asked Questions What is Adaptimmune Therapeutics' current short interest? Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 4,590,000 shares of ADAP short. 2.05% of Adaptimmune Therapeutics' shares are currently sold short. Learn More on Adaptimmune Therapeutics' current short interest. What is a good short interest ratio for Adaptimmune Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ADAP shares currently have a short interest ratio of 3.0. Learn More on Adaptimmune Therapeutics's short interest ratio. Which institutional investors are shorting Adaptimmune Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Adaptimmune Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Adaptimmune Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 2.05% of Adaptimmune Therapeutics' floating shares are currently sold short. Is Adaptimmune Therapeutics' short interest increasing or decreasing? Adaptimmune Therapeutics saw a decrease in short interest in April. As of April 15th, there was short interest totaling 4,590,000 shares, a decrease of 15.8% from the previous total of 5,450,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Adaptimmune Therapeutics' short interest compare to its competitors? 2.05% of Adaptimmune Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Adaptimmune Therapeutics: Compass Therapeutics, Inc. (9.30%), Atea Pharmaceuticals, Inc. (4.42%), Terns Pharmaceuticals, Inc. (8.55%), Aurora Cannabis Inc. (9.05%), Solid Biosciences Inc. (12.52%), Astria Therapeutics, Inc. (6.79%), Acelyrin, Inc. (5.04%), Cidara Therapeutics, Inc. (7.04%), Humacyte, Inc. (20.75%), Bright Minds Biosciences Inc. (1.77%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks. What does it mean to sell short Adaptimmune Therapeutics stock? Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. ADAP shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Adaptimmune Therapeutics? A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further. How often is Adaptimmune Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is April, 15 2025. More Short Interest Resources from MarketBeat Related Companies CMPX Short Interest Data AVIR Short Interest Data TERN Short Interest Data ACB Short Interest Data SLDB Short Interest Data ATXS Short Interest Data SLRN Short Interest Data CDTX Short Interest Data HUMA Short Interest Data DRUG Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ADAP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
